sur Zomedica Corp. (NASDAQ:ZOM)
Zomedica Reports 14% Revenue Growth in Q2 2025
Zomedica Corp., a veterinary health company, announced a 14% revenue increase to $7 million in Q2 2025, marking the 18th consecutive quarter of record year-over-year revenue growth. CEO Larry Heaton highlighted the strong performance of their therapeutic and diagnostic products, including PulseVet® and TRUFORMA®, which spurred this growth.
The Diagnostic segment grew by 86%, while Consumable sales rose by 21%, underpinning future recurring revenue opportunities. International sales improved by 13% from Q2 2024, fueled by both organic growth and new distributor partnerships. The company maintained healthy gross margins at 67%.
Operational costs reduced by $0.7 million due to ongoing internal cost-reduction initiatives. Zomedica reported a net loss of $7.4 million for the quarter, considerably lower than the $23.9 million loss seen in Q2 2024. The company's strategic focus remains on expanding its product portfolio internationally.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Zomedica Corp.